Log in

NASDAQ:ASMB - Assembly Biosciences Stock Price, Forecast & News

$17.59
+0.96 (+5.77 %)
(As of 12/11/2019 01:55 AM ET)
Today's Range
$16.38
Now: $17.59
$17.61
50-Day Range
$12.53
MA: $15.36
$17.59
52-Week Range
$8.13
Now: $17.59
$25.68
Volume211,071 shs
Average Volume552,003 shs
Market Capitalization$458.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
CUSIP92282210
Phone833-509-4583

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.80 million
Book Value$8.27 per share

Profitability

Net Income$-90,750,000.00
Net Margins-647.72%

Miscellaneous

Employees95
Market Cap$458.22 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.


Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by $0.03. The biopharmaceutical company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.45 million. Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%. View Assembly Biosciences' Earnings History.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Assembly Biosciences.

What price target have analysts set for ASMB?

4 equities research analysts have issued 1 year target prices for Assembly Biosciences' stock. Their forecasts range from $20.00 to $74.00. On average, they expect Assembly Biosciences' share price to reach $41.33 in the next twelve months. This suggests a possible upside of 135.0% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.

What is the consensus analysts' recommendation for Assembly Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.

What are Wall Street analysts saying about Assembly Biosciences stock?

Here are some recent quotes from research analysts about Assembly Biosciences stock:
  • 1. According to Zacks Investment Research, "Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. " (11/12/2019)
  • 2. Chardan Capital analysts commented, "We are also encouraged by the initiation of the phase Ib clinical trial (NCT03923478) for ABI-M201, Assembly’s rationally-designed consortium live biotherapeutic product for UC. We broadly favor this approach to microbiome medicines (MMs) development. Assembly reported $173.8 mm in cash and cash equivalents, providing a runway into 2021." (8/7/2019)

Has Assembly Biosciences been receiving favorable news coverage?

News coverage about ASMB stock has been trending very negative on Tuesday, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Assembly Biosciences earned a news impact score of -3.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Assembly Biosciences.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,290,000 shares, an increase of 477.3% from the October 31st total of 396,700 shares. Based on an average daily trading volume, of 548,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 10.1% of the company's shares are sold short. View Assembly Biosciences' Current Options Chain.

Who are some of Assembly Biosciences' key competitors?

What other stocks do shareholders of Assembly Biosciences own?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)
  • Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)
  • Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 63)
  • Mr. David J. Barrett CPA, Consultant (Age 43)

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Emerald Advisers LLC (1.70%), Emerald Mutual Fund Advisers Trust (1.61%), Barclays PLC (0.29%), Squarepoint Ops LLC (0.23%) and Russell Investments Group Ltd. (0.23%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.

Which institutional investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC, Assenagon Asset Management S.A., Barclays PLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Alps Advisors Inc.. View Insider Buying and Selling for Assembly Biosciences.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Voloridge Investment Management LLC, State Street Corp, Rhumbline Advisers and Millennium Management LLC. View Insider Buying and Selling for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $17.59.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $458.22 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.View Additional Information About Assembly Biosciences.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is http://www.assemblybio.com/.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel